2015年美国心脏学会(AHA)科学年会公布的一项研究表明，与广泛应用的Ⅲ类抗心律失常药物伊布利特相比，多通道阻滞剂维纳卡兰(vernakalant)可更快更好地恢复近期发作的房颤急诊患者窦性心律。

维纳卡兰是一种速效抗心律失常药物。研究者们纳入100例近期发作的房颤急诊患者。接受维纳卡兰和伊布利特治疗的患者分别为49例和51例，在这些患者中对比两种药物的疗效。

结果显示，维纳卡兰组恢复窦性心律的平均时间为10分钟，而伊布利特组则为26分钟；维纳卡兰组在90分钟内逆转成功率明显较高，达69%，而伊布利特组的这一比例为43%。两组均未发生严重治疗相关的并发症。

New drug restores irregular heart rhythm more often and much faster

By AMERICAN HEART ASSOCIATION NEWS

The multi-channel blocker vernakalant restored sinus rhythm more often and much faster than the widely used class III drug ibutilide in patients presenting to the emergency room with recent-onset atrial fibrillation (quivering or irregular heartbeat), according to a study presented at the American Heart Association’s Scientific Sessions 2015.

Vernakalant, like ibutilide, is a rapid-acting antiarrhythmic drug. Researchers compared the drugs’ effects by studying 100 patients with recent onset atrial fibrillation in a hospital emergency room.

Forty-nine patients received up to two infusions of vernakalant; 51 received intravenous ibutilide.

Researchers found:

• It took an average of 10 minutes to normalize heart rhythms with vernakalant, compared to 26 minutes with ibutilide.

• Conversion success within 90 minutes was notably higher in the vernakalant group (69 percent) compared to those who received ibutilide (43 percent).

No serious treatment-related complications occurred in either group.